Bioaerosol sampling of a ventilated patient with COVID-19

Morgan A. Lane, Emory University
Erik A. Brownsword, Emory University
Jill S. Morgan, Emory Healthcare
Ahmed Babiker, Emory University
Sharon A Vanairsdale, Emory Healthcare
G Marshall Lyon III, Emory University
Aneesh Mehta, Emory University
Jessica Mae Ingersoll, Emory University
William G. Lindsley, National Institute for Occupational Safety and Health
Colleen Kraft, Emory University

Journal Title: American Journal of Infection Control
Publisher: Elsevier: 12 months | 2020-01-01
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.ajic.2020.07.033
Permanent URL: https://pid.emory.edu/ark:/25593/vgqwk

Final published version: http://dx.doi.org/10.1016/j.ajic.2020.07.033

Copyright information:
© 2020 Association for Professionals in Infection Control and Epidemiology, Inc.

Accessed July 22, 2023 12:48 AM EDT
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Bioaerosol sampling of a ventilated patient with COVID-19

Morgan A. Lane MPH a,**, Erik A. Brownsword MPP a, Jill S. Morgan RN, BSN b, Ahmed Babiker MBBS c, Sharon A. Vanairsdale DNP b, G. Marshall Lyon MD, MMSc a, Aneesh K. Mehta MD a, Jess M. Ingersoll MT c, William G. Lindsley PhD d, Colleen S. Kraft MD, MSc a,b,c,*

a Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, GA
b Emory Healthcare, Atlanta, GA
c Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA
d NIOSH, Centers for Disease Control and Prevention, Morgantown, WV

** Alternative author.

Coronavirus disease 2019 (COVID-19) has now been detected in nearly every country in the world. The causative agent of COVID-19 has been identified as the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 Research is now being conducted to learn more about the transmission of the virus and the best ways to protect the general population, as well as health care personnel working at the frontlines of disease management.

SARS-CoV-2 is believed to spread primarily through droplets or direct contact, with hospital-acquired transmission increasingly becoming a problem. 2 Recent studies have shown that contact with contaminated surfaces is another possible method of transmission, with contamination of toilets and sinks being a priority in cleaning. 3, 4 However, regular hospital cleaning procedures appear to kill the virus, and viable virus in fecal samples is rarely identified. 3, 5 The virus may also be spread through aerosol-generating procedures, and it is possible that re-aerosolization of virus when health care workers remove personal protective equipment (PPE) increases exposure to the virus. 6

With the number of cases and hospitalizations increasing, in order to protect health care personnel and uninfected patients in health care settings, it is important to understand the characteristics of aerosols containing SARS-CoV-2. While studies conducted during the pandemic have found aerosols containing virus within the health care setting, none have explicitly examined aerosols within the room of a patient on a ventilator. 7 We sought to determine if aerosolized SARS-CoV-2 RNA could be found during the care of a ventilated patient who was being placed prone due to profound respiratory failure.

METHODS

Bioaerosol sampling

Ten NIOSH BC 251 2-stage cyclone samplers were used. 9 The NIOSH samplers separated particles into 3 size fractions, which are collected in a 15 mL centrifuge tube ( > 4 μm fraction), a 1.5 mL centrifuge tube (1-4 μm fraction) and on a filter cassette containing a 37-mm diameter, polytetrafluoroethylene filter with 2 μm pores (<1 μm...
fraction). Each sampler was connected with a 6.35-mm Tygon tubing
to an air sampling pump (PCXR-4, SKC, Eighty Four, PA) at a 3.5 L/min
flow rate.

Two samplers were placed approximately 102 cm and 152 cm
above the floor on each of 5 tripods. Three tripods were placed inside
the patient room, 1 in the bathroom within the patient room, and 1
in the anteroom (Fig 1). The patient room samplers were placed next
to the ventilator system (<2 ft away), in the corner along the same
wall as the ventilator system, and by the anteroom door (<3 ft from
the door). The anteroom sampler was placed <2 ft from the door to
the patient room and the sampler in the bathroom was placed by the
far wall (<2 ft from the toilet, <6 ft from the door). In an abundance
of caution and to simplify disinfection, the sampler tripods were
draped in plastic with holes cut out for the air intake and secured
with tape. The pump cases were draped with a disposable underpad
and secured to the tripods with tape.

Following a 6-hour sampling period, collected samples from each
sampler were processed as follows: 1) 1,000 µL viral transport
medium was added to the 15 mL tube, the tube was vortexed,
inverted and vortexed, then frozen at −80°C, 2) 400 µL viral transport
medium was added to the 1.5 mL tube, the tube was vortexed,
inverted and vortexed and frozen at −80°C, 3) sterile forceps were
used to remove the filter from its cassette and place it in a 15 mL
tube, 1,000 µL of viral transport medium was added to wet the entire
filter, and the tube was vortexed and stored at −80°C. RNA extraction
occurred on the m2000 (Abbott Molecular, Abbott Park, IL) with 600
µL of input sample volume, and sample elute of 50 uL. The extracted
samples underwent real-time polymerase chain reaction (RT-PCR)
for selected gene regions of the SARS-CoV-2 virus nucleocapsid (N1,
N2, N3) and human RNase P gene using a laboratory developed pro-
tocol adapted from the protocol published by the Centers for Disease
Control and Prevention. Following RNA extraction, a 20 µL reaction
was set up containing 5 µL of sample RNA, 8.5 µL of nuclease-
free water, 1.5 µL of combined primer/probe mix and 5µL of TaqPath
1-Step RT-qPCR Master Mix (ThermoFisher, Waltham, MA). Thermal
cycling was performed at 25°C for 2 minutes followed by 50°C for 15
minutes, followed by an initial denaturation at 95°C for 2 minutes,
followed by 45 cycles of amplification at 95°C for 3 seconds and 55.0°
C for 30 seconds. A previously characterized SARS-CoV-2 sample was
tested concurrently as a positive control. Fluorescence growth curves
which cross the threshold line within 40 cycles (<40 Ct) were consid-
ered positive.

Patient room

Sampling took place in an ICU-level airborne infection isolation
room (AIIR) in the Serious Communicable Diseases Unit at Emory
University Hospital. The AIIR has negative air pressure relative to the
anteroom (0.016-0.018 in of w.c.) with 20 air exchanges per hour,
laminar flow across the patient bed, and HEPA filtration. The adjoin-
ing anteroom has negative air pressure relative to the hallway.

Patient

The patient was confirmed PCR positive for COVID-19 the day
before sampling took place by both nasopharyngeal and oropharyn-
geal swabs. The patient’s legal authorized representative provided
informed consent under a protocol approved by the Emory IRB. Dur-
ing sampling, the patient was mechanically ventilated on a Hamilton
ventilator, with HEPA end exhaust and in-line heat and moisture
exchanger, via an 8.0 endotracheal tube with in-line heat and moisture
exchanger, via an 8.0 endotracheal tube with in-line, closed suction
device. Between 2 and 5 multidisciplinary health care workers,
including advanced practice providers, an attending physician, ICU
nurses, and a respiratory therapist, were present in the patient room
or anteroom during the entire 6-hour sampling period. With 5 health
care personnel present in the patient room, the patient was re-posi-
tioned from prone to supine. However, the patient failed to tolerate
supination, with decreasing oxygen saturation by SpO₂ monitoring
and increased peak pressures on the ventilator, and therefore
required re-proning. During this time, there was one brief disconnection of the proximal and distal part of the ventilator hose.

RESULTS

In total, 30 samples were collected, 3 from each sampler: one 15 mL centrifuge tube, one 1.5 mL centrifuge tube, and an additional 15 mL centrifuge tube containing the removed 37-mm filter. Two samples were unable to be used for testing: a 15 mL tube from the “Ventilator” tripod and a filter from the “Corner” tripod which fell on the floor. Of the 28 tested samples, 4 were positive for RP primer, indicating presence of human nucleic acid material. These included 2 samples from the patient room “Corner” 102 cm-high sampler, one sample from the room “Door” 102 cm-high sampler and one sample from the “Bathroom” 152-high cm sampler (Table 1). None of the 28 samples tested were positive for SARS-CoV-2 nucleic acid.

DISCUSSION

In order to protect health care personnel with appropriate PPE, there has been considerable discussion on what constitutes an aerosol-generating procedure. Our preliminary study shows that SARS-CoV-2 aerosols were not detected in an AIIR with a COVID-19 positive patient mechanically ventilated on a closed-suction device. This was particularly important because this patient was substantially manipulated through pronation and supination in the bed by many health care personnel during the 6 hours of sampling. His respiratory status was so poor that these aggressive measures were attempted to keep the patient able to be oxygenated. The health care workers were wearing powered air purifying respirators (PAPRs) as well as disposable gowns, 2 sets of gloves, and booties, in accordance with hospital policy. All PPE except for the PAPR were doffed in the patient room, with the PAPR being doffed in the anteroom.

Some studies have detected low amounts of SARS-CoV-2 RNA in aerosol samples collected in healthcare settings where patients were breathing and coughing into the environment while others have not.3–13 Our study was performed in an AIIR with laminar flow and a high air exchange rate with the patient on a ventilator with a HEPA filter. These early findings, based upon a single sampling event, suggest that the amount of airborne SARS-CoV-2 was very low.

However, it is important to note the limitations of our study. First, we cannot comment on the possibility of virus transmission in this setting, because this study only measured aerosols in the air and did not examine other potential pathways for virus transmission. Furthermore, the sampling may have been too dilute and the amount of RNA may have been below the limit of detection of 10 viral copies/mL. Second, aerosol sampling was conducted for only 1 patient during one 6-hour sampling period. Third, previous studies have shown that the filtration efficiency of ventilator exhaust filters varies widely, and thus these results cannot be assumed to apply to all ventilators and exhaust filters.14 Finally, although the patient was positive for COVID-19 in the upper respiratory tract and was diagnosed with acute respiratory distress syndrome, and therefore likely positive in the lower respiratory tract based on recent evidence,13 we cannot confirm that the patient was actively shedding virus on the day of sampling. Given we cannot understand the full extent of possible environmental contamination in the patient room with aerosol samples alone, surface sampling studies will be conducted along with any aerosol sampling in the future.

References